Page 4 - Immvira Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immvira pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immvira Pharma Today - Breaking & Trending Today

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

/PRNewswire/ ImmVira s breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has. ....

Prnewswire Immvira , Guoying Zhou ,

ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

/PRNewswire/ ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011 as intratumoral administration. ....

United States , Prnewswire Immvira , Bernard Roizman , China Phase , Grace Zhou , Health Care Amp Hospitals , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries , ஒன்றுபட்டது மாநிலங்களில் , சீனா கட்டம் , கருணை ஜூ , ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் , மருத்துவ மருந்துகள் , மருத்துவ சோதனைகள் ஆம்ப் மருத்துவ கண்டுபிடிப்புகள் ,

ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021

ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time. ....

American Society Of Clinical Oncology , Oncolytic Viruses , Preliminary Results , Clinical Phase , Recombinant Technology , Herpes Simplex Virus , Dose Escalation , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் ,

AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration

Share this article
Share this article
SHENZHEN, China, April 19, 2021 /PRNewswire/ On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolytic herpes simplex virus-1 expressing human interleukin-12 and anti-PD-1 antibody. ImmVira owns the global right for development and commercialization of MVR-T3011 via intravenous administration.
Oncolytic virus(OV) has been proven to inhibit tumor growth in a number of superficial tumors through intratumoral injection. From clinical studies, intratumoral injection of OV has been proved to provide effective treatment against tumor via its abscopal effect, transitions from immunologically cold to hot tumor and combination with other cancer therapies. However, to advanced tumors, especially the lesions of multiple metastasis are ideally treated v ....